Porsche reports U.S. retail sales for the first half of 2025
Atlanta., July 08, 2025 (GLOBE NEWSWIRE) — Porsche Cars North America, Inc. (PCNA) today announced that second-quarter retail deliveries in the United States totaled 19,812 vehicles, up 4.91 percent from the first quarter of 2025. Porsche maintained an H1 increase of 11.4 percent over the same period in 2024 making it the best half year in PCNA history.
'Despite a volatile market, our sales remained strong and interest in our cars continued to grow, in large part because of the outstanding customer experience delivered by our Porsche Centers,' said Timo Resch, President and CEO of PCNA. 'Our commitment to choice is driving our success, with a mix of ICE, hybrid and fully electric cars contributing to these results. While there may be uncertainty across many industries at the moment, it's been great to see that the passion amongst customers continues to thrive.'
The half year performance was led by the Macan with 14,563 units sold in the first six months, up 21.32 percent from 2024. A significant increase was also posted by the Panamera, with sales jumping from 1,675 cars during the same period in 2024 rising to 2,620 cars in 2025.
Year-to-date, 911 and 718 sales totaled 9,103 units, an increase of 3.1 percent over H1 last year, highlighting a continued healthy interest in Porsche two-door sports cars.
Porsche Approved Certified Pre-Owned (CPO) sales in the U.S. totaled 11,610 vehicles in the second quarter of 2025, up 15 percent from the same quarter in 2024.
Attachments Porsche reports U.S. retail sales for the first half of 2025
Porsche reports U.S. retail sales for the first half of 2025
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech, a global partner of biopharmaceutical manufacturing, have announced a partnership to accelerate Africa's biopharmaceutical industry and address the continent's urgent, dual health burdens in infectious and non-communicable diseases. This collaboration will focus on developing and manufacturing affordable, high-quality monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. The agreement will also cover joint initiatives in workforce development, process innovation, and technology transfer. "Africa is at a critical juncture in its health trajectory. We are battling a twin epidemic of infectious diseases and a rapidly rising burden of non-communicable diseases such as cancer and diabetes. Yet, lifesaving innovations often do not reach the continent due to high costs and late availability," said Dr. Menghis Bairu, CEO of Bio Usawa. "Our partnership with Sartorius Stedim Biotech is transformational—it allows us to bring advanced biomanufacturing technology to Africa, train a new generation of African scientists, and produce innovative biopharmaceuticals that are accessible and affordable for our people." The partnership includes the following core pillars: Research & Development: Sartorius Stedim Biotech will collaborate with Bio Usawa to develop state-of-the-art biosimilar cell lines tailored to therapeutic needs in Africa. Workforce Capacity Building: The companies will jointly design and deliver training programs for the African biopharma workforce, nurturing local talent for long-term sustainability. Technology Enablement: Sartorius Stedim Biotech will supply state-of-the-art bioprocessing equipment, media, buffers, and consumables for both upstream and downstream (drug substance and fill-finish) manufacturing. Optimization: Sartorius Stedim Biotech will provide its deep expertise in process optimization, ensuring robust, scalable, cost-effective and compliant manufacturing processes. Analytical and QC Support: Sartorius Stedim Biotech's capabilities in analytical characterization and quality control testing will strengthen Bio Usawa's product quality assurance framework. 'At Sartorius Stedim Biotech, we believe in enabling breakthroughs that improve human health, no matter where patients live,' said Michaela Pischke, Head of Business Area Separation Technologies at Sartorius Stedim Biotech. 'Our partnership with Bio Usawa reflects a shared ambition: supporting biopharmaceutical supply in Africa from the ground up. Through this collaboration, we aim not only to support technical innovation but also to empower local talent and infrastructure development to ensure long-term, self-sustaining impact.' With this partnership, Bio Usawa will leverage the extensive biotech product development, clinical trial, and regulatory expertise of its leadership team — across both developed and developing markets — to drive innovation tailored for Africa. This initiative represents a bold step forward in building Africa's health sovereignty, delivering on the promise of equitable access to life-saving innovations and shaping the future of healthcare on the continent. About Bio Usawa Inc. Bio Usawa is Rwanda's leading biotechnology company dedicated to democratizing access to life-saving biopharmaceuticals across Africa. Founded on the principle that geographic location should not determine healthcare outcomes, the company specializes in developing and manufacturing affordable, high-quality monoclonal antibodies targeting cancer, diabetes complications, infectious diseases, and autoimmune conditions. Bio Usawa's leadership team brings decades of experience from leading global biotech companies and international regulatory agencies. For more information, visit: About Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner to the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, more safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are listed on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. More than 9,900 employees work for customers around the globe. Visit our Newsroom or follow us on LinkedIn. Media Contacts: Contact Bio UsawaDaniel LevineLevine Media Group+1 510-280-5405danny@ Contact Sartorius Stedim Biotech GmbHLars HanfHead of BPS Marketing Communications+ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Monogram Technologies Announces World's First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery
The Procedure Utilized Monogram's mBôs TKA System Performed in India with Shalby Hospitals Groundbreaking Procedure Delivers the World's First Autonomous Saw-Based Robotic TKA Surgery on a Live Patient AUSTIN, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced that on Saturday, July 26, 2025, Monogram completed the first ever fully autonomous saw-based robotic knee replacement procedure on a live patient. The procedure was performed at the Krishna Shalby Hospital in Ahmedabad India, as part of Monogram's multi-center clinical trial in India for the Monogram TKA 1: From left to right, Pankajkumar Yadav, Dr. Douglas Unis, Benjamin Sexson, Dr. Vikram Shah, Pachore, Kamran Shamaei, Dr. Jayesh Patil, Aniruddh Nayak As previously announced, Monogram and Shalby partnered to evaluate the safety and effectiveness of the mBôs TKA System with the Consensus CKS implant, which is substantially equivalent to the Monogram mPress implants for regulatory purposes. On April 29, 2025, Monogram obtained regulatory approval from India's Central Drugs Standard Control Organization ("CDSCO") to import its mBôs TKA system to conduct a multi-center clinical investigation evaluating the safety and effectiveness of the Monogram TKA System. The clinical trial includes 102 total knee replacement procedures, with a three-month clinical follow-up, conducted across multiple sites in India. 'The first fully autonomous knee replacement on a live patient using Monogram's TKA System is a tremendous milestone for the Company. The procedure marks the culmination of years of hard work and dedication by our incredible team. I feel honored and proud to work with such incredible and dedicated individuals at Monogram. The system appears to have flawlessly executed the plan based on intraoperative surgeon evaluation, including intraoperative laxity estimation and achievement of planned alignment. I believe Monogram's product will have a significant positive impact on the standard of care for orthopedic medicine in the years to come,' said Benjamin Sexson, CEO of Monogram Technologies. 'Watching the ease with which the system cut and executed the procedure was incredibly fulfilling. The safety and accuracy of the system were on obvious display. It really was an amazing moment watching Dr. Patil realize that robots can be more than marketing gimmicks but tools that actually change how knee replacements can be done better, said founder Dr. Douglas Unis. 'Based on years of evaluating technology, watching this surgery was the final validation I needed to know with certainty that we have a groundbreaking product. It was incredible that there was so little stress, given the level of autonomy and first-time use on a living person. It was flawless.'Figure 2: Post-operative x-ray. Intra-operative stressed laxity and limb alignment, and post-operative stressed laxities and limb alignment were assessed. 'Observing the flawless execution of this surgical plan was a highlight of my career and incredibly fulfilling. Patient safety has been painstakingly considered in virtually every aspect of our system. Our goal is to have the most efficient, most accurate and safest robot in the world. I am incredibly proud of the hard work of our team and to have had the opportunity to help build this technology,' said Kamran Shamaei, Chief Technical Officer. 'I feel proud to have played a part in the development of the Monogram TKA System and to have been a member of this incredible team,' said Ani Nayak, Sr. Manager of Clinical R&D. 'As the individual responsible for the execution of this trial I feel a huge weight of responsibility. To see the system do its job with such low stress and execute the surgical plan as it did was extremely exciting. I believe our product will have a significant clinical impact globally.' Strategic partner Shalby Limited (NSE: SHALBY) ("Shalby"), one of the world's largest orthopedic hospital groups, will support the 102-patient clinical investigation evaluating the safety and effectiveness of the Monogram TKA System, one of the world's first saw-based autonomous robots. 'I founded Shalby Hospitals to be a world-renowned center of excellence and innovation for joint replacement surgeries,' said Dr. Vikram Shah, founder of Shalby Hospitals. 'My vision has always been to pioneer advanced technologies in the field of orthopedic medicine. Having performed thousands of surgeries, I was deeply impressed by what the Monogram team has accomplished and by what was achieved in this surgery, and I look forward to supporting the introduction of this state-of-the-art robotic system, which reaffirms Shalby's commitment to leading innovation and excellence in joint replacement surgeries.' The U.S. Food and Drug Administration (FDA) recently granted 510(k) clearance for Monogram's mBôs semi-autonomous TKA System. Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. recently announced they entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram. About Monogram Technologies Inc. Monogram Technologies (NASDAQ: MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics. To learn more, visit Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the Company's filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. Investor Relations Chris TysonExecutive Vice PresidentMZ North AmericaDirect: 949-491-8235MGRM@ Photos accompanying this announcement are available at: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Li Auto Inc. Launches Li i8, a Six-Seat Battery Electric Family SUV
BEIJING, China, July 29, 2025 (GLOBE NEWSWIRE) -- Li Auto Inc. ('Li Auto' or the 'Company') (Nasdaq: LI; HKEX: 2015), a leader in China's new energy vehicle market, today officially launched Li i8, a six-seat battery electric family SUV. As an SUV of the new era, Li i8 combines the all-terrain capabilities of off-road vehicles, the handling dynamics of sedans, and the comfort of MPVs, redefining family mobility with an all-new driving and riding experience. Li i8 offers three trims: Pro, Max and Ultra, which will retail for RMB321,800, RMB349,800 and RMB369,800, respectively. Deliveries of Li i8 will commence on August 20, 2025. Below is an overview of Li i8. For more details, please visit Li Auto's official website. A New High-Voltage BEV Platform Li Auto has developed a new high-voltage battery electric platform for Li i8, featuring an in-house developed electric drive system, 5C battery pack, and a nationwide 5C super charging network. 1) Proprietary Electric Drive System: Ultra-Quiet, Ultra-Efficient Li Auto's in-house developed electric drive system is designed to minimize noise and energy consumption. Its proprietary rotor-stator structure and transmission system can effectively reduce vibration and noise inside the Li i8 cabin, achieving industry-leading cabin quietness. Additionally, Li i8's electric drive system incorporates in-house developed silicon carbide power chips and modules, offering high efficiency, low losses, and rapid heat dissipation for enhanced energy savings. Li Auto also built its own motor factory to ensure the full implementation of in-house technologies. Switch Auto Insurance and Save Today! Great Rates and Award-Winning Service The Insurance Savings You Expect Affordable Auto Insurance, Customized for You 2) In-House Developed Ternary Lithium 5C Super Charging Battery Pack Li i8 is equipped with 90.1 kilowatt-hours and 97.8 kilowatt-hours ternary lithium 5C super charging battery pack options. With all-wheel drive offered as standard, Li i8 achieves a CLTC range of 670 kilometers and 720 kilometers for the 90.1 kilowatt-hours and 97.8 kilowatt-hours battery pack options, respectively. The in-house developed drive motor and low-drag design contribute to Li i8's industry-leading range attainment rate. Paired with an industry-leading battery thermal management system, Li i8 ensures sustained high-power charging, achieving a 500-kilometer driving range with just 10 minutes of charging. Furthermore, based on the Company's battery lifespan tests, Li i8's battery health remains above 80% after 1,500 full charge-discharge cycles in super charging mode. 3) The Largest Super Charging Network Among Chinese Automakers To support the rollout of BEVs, Li Auto has built the largest super charging network among Chinese automakers, with 3,000 super charging stations in operation. This network includes approximately 1,000 highway stations covering nine major east–west and nine major north–south highway routes, with an average spacing of about 150 kilometers, along with 2,000 urban stations across over 250 Design Li i8's avant-garde yacht-inspired design achieves low drag, exceptional space utilization, and outstanding visibility. With a drag coefficient of 0.218, the vehicle delivers reduced wind noise and energy consumption. As a large SUV with dimensions of 5,085 millimeters in length, 1,960 millimeters in width, 1,740 millimeters in height, and a 3,050-millimeter wheelbase, its interior space surpasses that of many full-size SUVs. Additionally, Li i8 provides every family user on board with excellent visibility. SUV of a New Era The combined strengths of its outstanding off-road capabilities, handling, and spaciousness position Li i8 as an exceptional SUV for a new era. Li i8 boasts an off-roader's passability, slope-climbing power, and ability to handle rough terrains. In terms of off-road performance, the Li i8 comes standard with a dual-chamber Li Magic Carpet air suspension, offering four adjustable height settings and a maximum ground clearance of 196 millimeters. Additionally, Li i8 is equipped with a dual-motor, all-wheel drive system in the standard configuration across all trims, enabling it to handle a wide range of challenging road conditions. Li i8 delivers sedan-like handling stability, performance, and ease of entry and exit through its battery electric low-center-of-gravity design, a body torsional stiffness of 49,500 Nm/degree, front double-wishbone and rear five-link suspension, a 0-100 km/h acceleration as quick as 4.5 seconds, and a minimum second-row side sill ground clearance of 401 millimeters. Li i8 offers MPV-like premium spaciousness and comfort. Its new wraparound-style seats feature optimized backrest and cushion surfaces, delivering enhanced support and hugging comfort. Li i8 also features a zero-gravity seat on the right side of the second row, a third row comparable to top MPVs, and a trunk depth of 565 millimeters when all three rows are in use, easily meeting the travel needs of large families. Li i8 can also be equipped with a large floating table, delivering an experience rivaling that of the Li MEGA. Industry-Leading Safety Capabilities For passive safety, Li i8 adopts a multi-path force transmission design in the front compartment, featuring three longitudinal force transmission paths to enhance energy dispersion during frontal collisions. The front compartment integrates 11 circular energy-absorbing structures, which effectively absorb and dissipate collision energy, ensuring overall vehicle safety and significantly enhancing the structural integrity of the occupant cabin. Li i8 also features comprehensive airbag protection with extended side curtain airbags and door handles designed to remain unlockable even in power failures. It is also engineered to meet stringent eco-health standards. Additionally, its battery has undergone rigorous safety testing under extreme conditions such as submersion and freezing, complying with rigorous safety protocols. On active safety, all Li i8 trims come standard with LiDAR sensors and are equipped with enhanced automatic emergency steering (AES) to effectively mitigate collision risks from other vehicles. An All-New Assisted Driving and Smart Space Experience In terms of assisted driving, Li i8 Pro comes standard with the Li AD Pro assisted driving system, equipped with a Horizon Robotics J6M chip delivering total computing power of 128 TOPS. The Li i8 Max and Ultra models are equipped with the advanced Li AD Max assisted driving system, featuring an NVIDIA Thor-U chip with a total computing power of 700 TOPS. With the launch of urban NOA on the Horizon Robotics J6M platform by year-end, the assisted driving capabilities of Li AD Pro will be significantly enhanced. The Li AD Max will integrate Li Auto's self-developed VLA driver large model, which possesses understanding, reasoning, memory, and communication capabilities, evolving through reinforcement learning into an increasingly intuitive personal driver. Combining spatial intelligence, linguistic intelligence, and behavioral strategies, the VLA driver large model leverages a human-like technical architecture to deliver notable improvements in safe driving, smoothness and comfort, three-point turns, continuous task execution, and underground parking. The development of the VLA driver large model benefited from Li Auto's R&D advantages in data, algorithms, computing power, and engineering capabilities, including optimized data allocation, the use of generated data, high model evaluation efficiency, a closed loop of reinforcement learning, as well as increasing investments in computing power, robust quantitative accuracy, and multi-platform deployment capabilities. The VLA driver large model will be fully rolled out to AD Max models equipped with Orin-X and Thor-U chips alongside the delivery of Li i8. In terms of smart space, Li Auto's in-house foundation model MindGPT-powered Li Xiang Tong Xue has evolved from a voice assistant to Li Xiang Tong Xue Agent. It can independently utilize tools, resolve complex tasks, and possess personalized memory. Nearly all in-vehicle functions of Li i8 have undergone tool-based integration for Li Xiang Tong Xue Agent, including electric air vents for climate control and windshield wipers. For complex tasks, Li Xiang Tong Xue Agent leverages Li Auto's advanced model capabilities to understand user intent and achieve goals efficiently. For example, it can autonomously invoke tools like the Meituan app to fulfill in-store food pickup requests or activate the vehicle's external cameras to scan QR codes in parking lots for payment. Examples also include the industry-first Desktop Master functionality that enables user-programmable code generation and the creation of tools, content, and services. Furthermore, with the June rollout of Face ID and the new family account system, Li Xiang Tong Xue Agent can remember information about each individual to deliver personalized experiences while ensuring data security—making daily use more convenient, thoughtful and emotionally resonant for every family member. Brand Upgrade At the launch event, Li Auto announced its brand upgrade, committing to providing a high-quality home, a premium private space for a diverse range of consumers while meeting the needs of family users. The Company will uphold its brand value proposition of 'private space, deep connection, and cherished experience,' while continuing to invest in products and intelligence. Through the creation of sophisticated, liberating, and distinctive mobile spaces, Li Auto aims to fulfill its mission: Create a Mobile Home, Create happiness. About Li Auto Inc. Li Auto Inc. is a leader in China's new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric vehicles. Its mission is: Create a Mobile Home, Create Happiness (创造移动的家,创造幸福的家). Through innovations in product, technology, and business model, the Company provides families with safe, convenient, and comfortable products and services. Li Auto is a pioneer in successfully commercializing extended-range electric vehicles in China. While firmly advancing along this technological route, it builds platforms for battery electric vehicles in parallel. The Company leverages technology to create value for users. It concentrates its in-house development efforts on proprietary range extension systems, innovative electric vehicle technologies, and smart vehicle solutions. The Company started volume production in November 2019. Its current model lineup includes a high-tech flagship family MPV, four Li L series extended-range electric SUVs, and one Li i series battery electric SUV. The Company will continue to expand its product lineup to target a broader user base. For more information, please visit: Safe Harbor Statement This press release contains statements that may constitute 'forward-looking' statements pursuant to the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to,' 'challenges,' and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the 'SEC') and The Stock Exchange of Hong Kong Limited (the 'HKEX'), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Auto's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Auto's strategies, future business development, and financial condition and results of operations; Li Auto's limited operating history; risks associated with extended-range electric vehicles and high-power charging battery electric vehicles; Li Auto's ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Auto's ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Auto's ability to compete successfully; Li Auto's ability to build its brand and withstand negative publicity; cancellation of orders for Li Auto's vehicles; Li Auto's ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Auto's filings with the SEC and the HKEX. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: Li Auto RelationsEmail: ir@ Christensen AdvisoryRoger HuTel: +86-10-5900-1548Email: Li@ Photos accompanying this announcement are available at
